Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25665394 | 0.89 | NCEH1 (0.39) | LMNANCEH1RXFP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL23474092 | 0.88 | LCK (0.41) | LMNAALOX5APFEN1MAPK1GABRA5 | |
| SCHEMBL23474121 | 0.80 | DGAT1 (0.43) | LMNAALOX5APFEN1MAPK1GABRA5 | |
| SCHEMBL19808916 | 0.76 | MAPK1 (0.42) | LMNAALOX5APFEN1HSD17B10MAPK1 | |
| SCHEMBL24313817 | 0.74 | LMNA (0.46) | LMNAMAPK1GABRA5L3MBTL1KDM4E | |
| SCHEMBL1797972 | 0.74 | HSPB1 (0.54) | LMNAMAPK1GABRA5L3MBTL1SMN1; SMN2 | |
| SCHEMBL19808852 | 0.72 | SCN9A (0.48) | LMNAMAPK1GABRA5L3MBTL1SMN1; SMN2 | |
| SCHEMBL23474091 | 0.72 | MAPK1 (0.45) | LMNAMAPK1GABRA5LCKL3MBTL1 | |
| SCHEMBL19808885 | 0.71 | GABRA5 (0.46) | LMNAMAPK1GABRA5L3MBTL1KDM4E | |
| SCHEMBL19808889 | 0.71 | LMNA (0.42) | LMNAALOX5APFEN1MAPK1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-112898289-B | Compounds for modulating FXR activity and uses thereof | 甘莱制药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-112891348-B | Use of phenyl isoxazolyl methylene-naphthalene-ether derivatives and pharmaceutical compositions | 甘莱制药有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2021109713-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109712-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021108974-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD (CN) | 2021-06-10 | — | — | WO | disclosed |
| CN-112891348-A | Use and pharmaceutical composition of phenyl isoxazolyl methylene-naphthalene-ether derivatives | 甘莱制药有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112898289-A | Compounds for modulating FXR activity and uses thereof | 甘莱制药有限公司 | 2021-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | LMNA 51/4885NCEH1 2917/4885ALOX5AP 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.